GSK's Stock Wobbles Amid Zantac Litigation Drama

The share price of the company in question experienced a significant drop in 2022, which aligns with the timeline of the Zantac-related legal developments and the subsequent investor reaction to the potential liabilities faced by the pharmaceutical companies involved.
Following the initial plunge, the share price has shown signs of recovery throughout 2023, yet it has not returned to its pre-drop levels, indicating ongoing investor concern regarding the outcome of the litigation and its impact on the company's financial health.